What is Opus Genetics?
Opus Genetics is a clinical-stage biopharmaceutical company operating within the biotechnology and ophthalmology sectors. The company is dedicated to pioneering innovative gene therapies aimed at treating inherited retinal diseases, as well as other retinal and refractive disorders. Headquartered in the United States, Opus Genetics focuses its research and development efforts on ophthalmic gene therapies, striving to create treatments that can correct or compensate for genetic defects responsible for retinal degeneration. Their mission is to translate scientific discoveries into safe and effective solutions for patients suffering from both rare and common retinal conditions, positioning themselves as a leader in global ophthalmic gene therapy innovation.
How much funding has Opus Genetics raised?
Opus Genetics has raised a total of $164.4M across 2 funding rounds:
Angel/Seed
$4.5M
Stock/Share Issuance
$159.9M
Angel/Seed (2023): $4.5M with participation from North Carolina Biotechnology Center
Stock/Share Issuance (2026): $159.9M led by Oberland Capital
Key Investors in Opus Genetics
North Carolina Biotechnology Center
The North Carolina Biotechnology Center is a key player in life science economic development, supporting the transformation of research into marketable products across biopharma and therapeutics. They foster innovation and commercialization through connections, funding, and networking.
Oberland Capital
Oberland Capital is a private investment firm specializing in flexible financing solutions for the global healthcare industry, managing substantial assets to accelerate product development and commercialization.
What's next for Opus Genetics?
The substantial enterprise-level investment in Opus Genetics signals a strategic push towards scaling its operations and advancing its pipeline of gene therapies. This capital infusion is expected to accelerate clinical trials, expand research capabilities, and potentially facilitate market entry for their vision-preserving and vision-restoring treatments. The company's focus on addressing unmet needs in ophthalmology positions it for significant growth and impact in the biopharmaceutical landscape.
See full Opus Genetics company page
